secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001447362-23-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences expects 2022 revenue to exceed top end of $132-137M guidance
-------------------------------------------------------------------------------

- Total test reports in 2022: 44,338, up 58% YoY from 28,118.
- DecisionDx-Melanoma volume 27,797 (+37% YoY); DecisionDx-SCC 5,966 (+70% YoY).
- Year-end cash & short-term investments ~$259M ($123M cash + $136M short-term).
- Q4 2022 test reports 12,563 (+52% YoY from 8,242); TissueCypher and IDgenetix newly contributed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/0001447362-23-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/cstl-20230108.htm
  HTML page:      https://secwatch.observer/filing/0001447362-23-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer